Komodo Health’s Real-World Evidence and Technology Platform Powers Two Real-World Analyses in Primary Biliary Cholangitis for Intercept Pharmaceuticals
Retrieved on:
목요일, 11월 10, 2022
Software, Professional Services, Data Management, Biometrics, Venture Capital, Technology, Artificial Intelligence, Health Technology, Data Analytics, Clinical Trials, Biotechnology, Health, Komodo, Sentinel, American Association for the Study of Liver Diseases, Institute of Liver and Biliary Sciences, Intercept, Technology, Association, Population, AASLD, PBC, Intercept Pharmaceuticals, Safety, Machine learning, Decision-making, American Association, RWE, Gaps, Patient, Algorithm, Primary biliary cholangitis, Industry, Liver disease, FDA, Pharmaceutical industry, Medical imaging, Medical device, Obeticholic acid
Today, Komodo Health announced a collaboration with Intercept Pharmaceuticals (Nasdaq: ICPT), powering clinical research and new real-world evidence with Komodos platform.
Key Points:
- Today, Komodo Health announced a collaboration with Intercept Pharmaceuticals (Nasdaq: ICPT), powering clinical research and new real-world evidence with Komodos platform.
- Intercept leveraged Komodos technology to fuel a retrospective study on long-term outcomes for Ocaliva, a therapeutic to treat primary biliary cholangitis (PBC), a rare liver disease.
- Intercept initially developed a placebo-controlled clinical outcomes study, COBALT, to evaluate patients with advanced PBC using Ocaliva, but terminated it due to feasibility challenges.
- Arif Nathoo, Komodo Health Co-Founder and Chief Executive Officer, said: "Komodo launched Sentinel to enable real-world evidence at scale.